[go: up one dir, main page]

MX2009011357A - Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos. - Google Patents

Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.

Info

Publication number
MX2009011357A
MX2009011357A MX2009011357A MX2009011357A MX2009011357A MX 2009011357 A MX2009011357 A MX 2009011357A MX 2009011357 A MX2009011357 A MX 2009011357A MX 2009011357 A MX2009011357 A MX 2009011357A MX 2009011357 A MX2009011357 A MX 2009011357A
Authority
MX
Mexico
Prior art keywords
tetrahydropyrido
methods
pyrimidinone derivatives
pyrimidinone
derivatives
Prior art date
Application number
MX2009011357A
Other languages
English (en)
Inventor
Craig D Boyle
Bernard R Neustadt
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009011357A publication Critical patent/MX2009011357A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente inversión se refiere a métodos de uso de los Derivados de Tetrahidropirido[4,3-d]Pirimidinona para el tratamiento o prevención de la obesidad, diabetes, un trastorno metabólico, una enfermedad cardiovascular o un trastorno relacionado con la actividad de GPR119 en un paciente.
MX2009011357A 2007-04-20 2008-04-17 Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos. MX2009011357A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92543207P 2007-04-20 2007-04-20
US95333007P 2007-08-01 2007-08-01
PCT/US2008/004997 WO2008130615A1 (en) 2007-04-20 2008-04-17 Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009011357A true MX2009011357A (es) 2009-11-05

Family

ID=39767076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011357A MX2009011357A (es) 2007-04-20 2008-04-17 Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.

Country Status (7)

Country Link
US (1) US20100113330A1 (es)
EP (1) EP2148679A1 (es)
JP (1) JP2010524944A (es)
CN (1) CN101686980A (es)
CA (1) CA2684618A1 (es)
MX (1) MX2009011357A (es)
WO (1) WO2008130615A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074271A1 (ja) * 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤
CN102316875A (zh) 2009-02-13 2012-01-11 贝林格尔.英格海姆国际有限公司 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
CN102382111B (zh) * 2011-09-06 2013-02-06 上海师范大学 硫代四氢吡啶并二氢嘧啶酮衍生物、其制备及应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
US10183947B2 (en) * 2015-05-04 2019-01-22 Astrazeneca Ab Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281602A (en) * 1993-04-23 1994-01-25 American Cyanamid Company Angiotensin II receptor blocking 2,3,6-substituted 5,6,7,8-tetrahydro-pyrido[4,3-D]pyrimidin-4(3H)-ones
EP0635263A3 (en) * 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
JPH0827149A (ja) * 1994-07-08 1996-01-30 Meiji Seika Kaisha Ltd ピリミジノン誘導体およびその塩
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
CN101754961A (zh) * 2007-04-20 2010-06-23 先灵公司 嘧啶酮衍生物及其使用方法

Also Published As

Publication number Publication date
WO2008130615A1 (en) 2008-10-30
CA2684618A1 (en) 2008-10-30
US20100113330A1 (en) 2010-05-06
JP2010524944A (ja) 2010-07-22
EP2148679A1 (en) 2010-02-03
CN101686980A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MX2009011358A (es) Derivados de pirimidinona y metodos para su uso.
EP3150204A3 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
IL210778A0 (en) Pyrazolo [3,4]pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
ZA200901826B (en) Treating pain, diabetes, and lipid metabolism disorders
MX2010013020A (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
IL208246A0 (en) Polysubstituted 2-aryl-6-phenyl-imidazo[1,2-a]pyridine derivatives, and preparation and therapeutic use thereof
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
MY148723A (en) Use of pinolenic acid for the treatment of obesity
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
IL198481A0 (en) Pyrrole derivatives, preparation use of the same in therapy
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
IL211957A0 (en) Composition for the use in the treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
IL206420A0 (en) Azetidine derivatives, their preparation and their application in therapy
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
EP2021009A4 (en) METHOD FOR IMPROVING THE CREATINE KINASE METABOLISM AND THE CONCENTRATION FUNCTION OF THE HEART MUSCLES FOR THE TREATMENT OF HEART FAILURE
IL202474A0 (en) 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof